Invivyd (Invivyd) Purchase Of Property, Plant, Equipment : $-0.13 Mil (TTM As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Invivyd Purchase Of Property, Plant, Equipment?

Invivyd's purchase of property, plant, equipment for the three months ended in Mar. 2024 was $-0.14 Mil. It means Invivyd spent $0.14 Mil on purchasing property, plant, equipment. Invivyd's purchase of property, plant, equipment for the trailing twelve months (TTM) ended in Mar. 2024 was $-0.13Mil.

Compared with last quarter ($0.00 Mil in Dec. 2023 ), Invivyd spent more money on purchasing property, plant, equipment in Mar. 2024 ($-0.14 Mil).

Invivyd Purchase Of Property, Plant, Equipment Historical Data

The historical data trend for Invivyd's Purchase Of Property, Plant, Equipment can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Invivyd Purchase Of Property, Plant, Equipment Chart

Invivyd Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Purchase Of Property, Plant, Equipment

-0.08

-1.71

-0.62

Invivyd Quarterly Data
	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Purchase Of Property, Plant, Equipment	Get a 7-Day Free Trial										-0.62	0.01	-	-	-0.14

Invivyd Purchase Of Property, Plant, Equipment Calculation

The amount used to purchase PPE.

Purchase Of Property, Plant, Equipment for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.13 Mil.

Invivyd Purchase Of Property, Plant, Equipment Related Terms

Thank you for viewing the detailed overview of Invivyd's Purchase Of Property, Plant, Equipment provided by GuruFocus.com. Please click on the following links to see related term pages.

Invivyd (Invivyd) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Invivyd Inc (NAS:IVVD) » Definitions » Purchase Of Property, Plant, Equipment

Comparable Companies

Traded in Other Exchanges

N/A

Address

1601 Trapelo Road, Suite 178, Waltham, MA, USA, 02451

Website

https://www.invivyd.com

Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape.

Executives

Adimab, Llc	10 percent owner, other: See Remarks	7 LUCENT DRIVE, LEBANON NH 03766
William E. Duke	officer: Chief Financial Officer	C/O VALERITAS, INC., 750 ROUTE 202 SOUTH, SUITE 600, BRIDGEWATER NJ 08807
Sara Cotter	director	1735 MARKET STREET, FLOOR 23, PHILADELPHIA PA 19103
Allen Robert D. Iii	officer: Chief Scientific Officer	1601 TRAPELO ROAD, SUITE 178, WALTHAM MA 02451
Stacy Price	officer: Chief Tech. and Manuf. Officer	1601 TRAPELO ROAD, SUITE 178, WALTHAM MA 02451
Jeremy Gowler	officer: COO & CCO	1601 TRAPELO ROAD, SUITE 178, WALTHAM MA 02451
Rebecca Dabora	officer: Chief Tech and Manuf Officer	303 WYMAN STREET, SUITE 300, WALTHAM MA 02451
Peter Schmidt	officer: Chief Medical Officer	1601 TRAPELO ROAD, SUITE 178, WALTHAM MA 02451
Jill Andersen	officer: Chief Legal Officer, Secretary	303 WYMAN STREET, SUITE 300, WALTHAM MA 02451
Christine Lindenboom	director	1601 TRAPELO ROAD, SUITE 178, WALTHAM MA 02451
Frederick W Driscoll	officer: Interim CFO
David Hering	director, officer: Chief Executive Officer	303 WYMAN STREET, SUITE 300, WALTHAM MA 02451
Marc Elia	director, other: See Remarks	C/O SQZ BIOTECHNOLOGIES COMPANY, 200 ARSENAL YARDS BOULEVARD, SUITE 210, WATERTOWN MA 02472
M28 Capital Management Lp	other: See Remarks	700 CANAL STREET, 2ND FLOOR, STAMFORD CT 06902
Clive Meanwell	director, 10 percent owner	THE MEDICINES CO, 8 SYLVAN WAY, PARSIPPANY NJ 07054